Please confirm you are human (Sign Up for free to never see this)
← Back to Search
9 – Management Of Cardiac And Pulmonary Treatment–related Side Effects
Joseph R. Carver
Published 2011 · Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
This paper references
Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment.
M. Ewer (2005)
Adherence to anemia treatment guidelines in U.S. community oncology practices
L. Friedman (2007)
Chemotherapy agents and hypertension: A focus on angiogenesis blockade
Manish Jain (2007)
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
M. Marty (2005)
The update on the rationale, use and selection of β-blockers in heart failure
G. Giesler (2004)
Asymptomatic cardiac disease following mediastinal irradiation.
P. Heidenreich (2003)
Severe bleomycin-induced pneumonitis. Clinical features and response to corticosteroids.
D. White (1984)
Prolongation of the QT Interval and Ventricular Tachycardia in Patients Treated with Arsenic Trioxide for Acute Promyelocytic Leukemia
K. Ohnishi (2000)
Lenalidomide for the treatment of B-cell malignancies.
A. Chanan-Khan (2008)
Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate.
M. Telli (2008)
Surgical management of radiation-induced heart disease.
R. Veeragandham (1998)
Cardiac events in imatinib mesylate-treated chronic myeloid leukemia patients: A single institution experience.
M. Breccia (2008)
Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib.
T. Takano (2004)
Effect of arsenic trioxide on QT interval in patients with advanced malignancies.
J. Barbey (2003)
Severe cardiotoxicity during 5-fluorouracil chemotherapy: a case and literature report.
C. Kuropkat (1999)
Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.
L. Gianni (1995)
Hypersensitivity pneumonitis associated with the use of temozolomide
D. Koschel (2009)
Effect of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function and symptoms in early-stage Hodgkin's disease.
A. Hirsch (1996)
Double-blind randomised trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer
M. Levine (1994)
Coronary artery findings after left-sided compared with right-sided radiation treatment for early-stage breast cancer.
C. Correa (2007)
Reporting results of cancer treatment
A. Miller (1981)
Tolerance of bevacizumab in an older patient population: The Memorial Sloan-Kettering Cancer Center (MSKCC) experience
S. Richardson (2008)
Preclinical, pharmacologic, and phase I studies of gemcitabine.
A. Storniolo (1997)
Pulmonary complications following bone marrow transplantation.
T. Wah (2003)
Cardiovascular morbidity in long-term survivors of metastatic testicular cancer.
M. T. Meinardi (2000)
Gemcitabine and atrial fibrillation: a rare manifestation of chemotherapy toxicity.
D. Ferrari (2006)
Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies.
D. Rayson (2008)
Radiation-induced valvular disease is the logical consequence of irradiation
A. Tamura (2007)
Predicting fluorouracil toxicity: can we finally do it?
H. Ezzeldin (2008)
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial.
F. Boccardo (2005)
Complete Atrioventricular Block after Arsenic Trioxide Treatment in an Acute Promyelocytic Leukemic Patient
C. Huang (1999)
Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis.
S. Wu (2008)
2007 Chronic Angina Focused Update of the ACC/AHA 2002 Guidelines for the Management of Patients With Chronic Stable Angina
T. D. Fraker (2007)
Cardiac dysfunction in the trastuzumab clinical trials experience.
A. Seidman (2002)
Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy.
D. Cardinale (2000)
Mortality patterns over 34 years of breast cancer patients in a clinical trial of post-operative radiotherapy.
J. M. Jones (1989)
Thrombosis of Internal Carotid Artery after Cisplatin-Based Chemotherapy
J. Pretnar-Oblak (2006)
Cardiovascular disease as a long-term complication of treatment for testicular cancer.
R. Huddart (2003)
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.
H. Joensuu (2006)
Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.
E. Tan-chiu (2005)
Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism.
A. Lee (2005)
Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease.
C. Tebbi (2007)
Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials.
E. Perez (2008)
Mitral and tricuspid valve repair in patients with previous mediastinal radiation therapy.
J. Crestanello (2004)
The cardiotoxicity of anticancer agents.
D. V. Von Hoff (1982)
Vincristine‐induced myocardial infarction
Eugen M. Mandel (1975)
Pulmonary complications of radiation therapy.
R. Abratt (2004)
Radiation-associated cardiovascular disease.
M. Adams (2003)
Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study.
B. Monk (2009)
Clinical Cardiotoxicity of 5‐Fluorouracil
D. Keefe (1993)
Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators.
M. Bristow (1996)
Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma.
M. Schmidinger (2008)
Acute arrhythmogenicity of doxorubicin administration
J. Steinberg (1987)
K. Shan (1996)
American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants.
M. Hensley (2009)
Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide.
P. Westervelt (2001)
Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study.
S. Rivkin (1994)
Clinical features of interstitial lung disease induced by standard chemotherapy (FOLFOX or FOLFIRI) for colorectal cancer.
T. Shimura (2010)
Increased risk of stroke and transient ischemic attack in 5-year survivors of Hodgkin lymphoma.
M. D. De Bruin (2009)
BCIRG 007: First overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC)
M. Pegram (2007)
Hypomagnesemia, renal dysfunction, and Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin
N. Vogelzang (1985)
The MASTER registry on venous thromboembolism: description of the study cohort.
G. Agnelli (2008)
American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer.
G. Lyman (2007)
The safety of long-term bevacizumab use: Results from the BRiTE observational cohort study (OCS)
D. Purdie (2008)
Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.
F. Kabbinavar (2003)
Severe vascular toxicity associated with cisplatin‐based chemotherapy
F. Içli (1993)
An evaluation of the cardiotoxicity of imatinib mesylate.
A. Ribeiro (2008)
Vascular toxicity and the mechanism underlying Raynaud's phenomenon in patients treated with cisplatin, vinblastine and bleomycin.
S. Hansen (1990)
Sorafenib in advanced clear-cell renal-cell carcinoma.
B. Escudier (2007)
No long-term increase in cardiac-related mortality after breast-conserving surgery and radiation therapy using modern techniques.
A. Nixon (1998)
Tissue Doppler imaging in detection of myocardial dysfunction in survivors of childhood cancer treated with anthracyclines.
L. Kapusta (2000)
Quality of internal thoracic artery grafts after mediastinal irradiation.
B. Gansera (2007)
Noncardiogenic pulmonary edema: an unusual and serious complication of anticancer therapy.
E. Briasoulis (2001)
Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.
M. Zangari (2001)
FDA drug approval summaries: oxaliplatin.
A. Ibrahim (2004)
Early detection of cardiotoxicity during chemotherapy using biomarkers
D. Lenihan (2007)
MYOCARDIAL INFARCTION FOLLOWING VINBLASTINE TREATMENT
J. Lejonc (1980)
Rates of Torsades de Pointes Associated with Ciprofloxacin, Ofloxacin, Levofloxacin, Gatifloxacin, and Moxifloxacin
R. Frothingham (2001)
Diagnosis and management of drug-associated interstitial lung disease
N. Müller (2004)
Cerebrovascular disease in childhood cancer survivors
Brannon Morris (2009)
Late cardiac mortality and morbidity in early-stage breast cancer patients after breast-conservation treatment.
E. Harris (2006)
5-Fluorouracil related toxic myocarditis: case reports and pathological confirmation.
Z. Sasson (1994)
Myocardial toxic effects during recombinant interleukin-2 therapy.
R. Nora (1989)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
H. Hurwitz (2004)
Executive summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline.
K. Adams (2006)
Electrocardiographic and Cardiovascular Effects of the 5-Hydroxytryptamine3 Receptor Antagonists
R. Navari (2003)
A prospective study of pulmonary function in patients treated with paclitaxel and carboplatin
I. Dimopoulou (2002)
Pulmonary complications of novel antineoplastic agents for solid tumors.
B. Vahid (2008)
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
D. Slamon (1987)
Cardiac toxicity 4 to 20 years after completing anthracycline therapy.
L. Steinherz (1991)
Dose-volume factors contributing to the incidence of radiation pneumonitis in non-small-cell lung cancer patients treated with three-dimensional conformal radiation therapy.
E. Yorke (2002)
Coronary spasm induced by capecitabine mimicks ST elevation myocardial infarction
P. Scott (2008)
Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC).
A. Torbicki (2008)
Ara-C lung: noncardiogenic pulmonary edema complicating cytosine arabinoside therapy of leukemia.
Helen M. Haupt (1981)
Risk of cardiac death after adjuvant radiotherapy for breast cancer.
S. Giordano (2005)
Heart transplantation for radiation-associated end-stage heart failure
N. Handa (2000)
Cardiovascular late effects and the ongoing care of adult cancer survivors.
J. Carver (2008)
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
L. Saltz (2008)
Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer.
N. Robert (2006)
Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults.
O. Hequet (2004)
Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood.
S. Lipshultz (1991)
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib
T. F. Chu (2007)
Atrial Fibrillation Induced by Gemcitabine Treatment in a 65-Year-Old Man
Y. Tavil (2007)
Diastolic dysfunction after mediastinal irradiation.
P. Heidenreich (2005)
Immune-mediated side-effects of cytokines in humans.
T. Vial (1995)
Injury to the lung from cancer therapy: clinical syndromes, measurable endpoints, and potential scoring systems.
S. McDonald (1995)
Cardiac risk after mediastinal irradiation for Hodgkin's disease.
C. Glanzmann (1998)
Risk factors for doxorubicin-induced congestive heart failure.
D. V. Von Hoff (1979)
Capecitabine-related cardiotoxicity: recognition and management.
M. Saif (2008)
Bronchial stenosis and sclerosing mediastinitis: an uncommon complication of external thoracic radiotherapy.
S. T. Dechambre (1998)
Introducing a new entity: chemotherapy-induced arrhythmia.
M. Guglin (2009)
Doxorubicin-induced second degree and complete atrioventricular block.
S. Kilickap (2005)
USE OF CHEMOTHERAPY PLUS A MONOCLONAL ANTIBODY AGAINST HER 2 FOR METASTATIC BREAST CANCER THAT OVEREXPRESSES HER 2
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma
A. Palumbo (2008)
Capecitabine cardiotoxicity--case reports and literature review.
N. Manojlovic (2008)
Diagnosis of disease caused by Mycobacterium avium complex.
M. Tsukamura (1991)
Cytoprotection for radiation-associated normal tissue injury.
J. Mao (2008)
Lifetime Risk for Developing Congestive Heart Failure: The Framingham Heart Study
D. Lloyd-Jones (2002)
Active lung fibrosis up to 17 years after chemotherapy with carmustine (BCNU) in childhood.
B. O'Driscoll (1990)
Coronary artery bypass grafting in patients with previous mediastinal radiation therapy.
N. Handa (1999)
Gemcitabine-induced atrial fibrillation: a hitherto unreported manifestation of drug toxicity.
D. Santini (2000)
Different anthracycline derivates for reducing cardiotoxicity in cancer patients.
E. C. van Dalen (2010)
Capecitabine-induced coronary vasospasm.
Y. Goldsmith (2008)
Interstitial Lung Disease Induced by Drugs and Radiation
P. Camus (2004)
Sudden death during doxorubicin administration
J. Wortman (1979)
Management of malignant pleural effusions.
V. Antony (2001)
Congestive heart failure is a rare event in patients receiving imatinib therapy.
E. Atallah (2007)
Highlights from: 5-Fluorouracil Drug Management Pharmacokinetics and Pharmacogenomics Workshop; Orlando, Florida; January 2007.
J. Bertino (2007)
The predictive role of plasma TGF-beta1 during radiation therapy for radiation-induced lung toxicity deserves further study in patients with non-small cell lung cancer.
Lujun Zhao (2008)
Pulmonary complications following bone marrow transplantation.
C. K. Chan (1990)
Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study.
S. Kudoh (2008)
Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.
S. Yusuf (1991)
Cardiac disease following treatment of Hodgkin's disease in children and adolescents.
S. Hancock (1993)
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.
F. Scappaticci (2007)
Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone
H. Nakamae (2005)
BNP as a marker of the heart failure in the treatment of imatinib mesylate.
Y. Park (2006)
Combination of isosorbide dinitrate and hydralazine in blacks with heart failure.
A. Taylor (2004)
Thromboembolic events during treatment with thalidomide.
E. Urbauer (2002)
Cardiotoxicity associated with high-dose cyclophosphamide therapy.
J. Gottdiener (1981)
Fatal bleomycin pulmonary toxicity in the west of Scotland 1991-95: a review of patients with germ cell tumours.
A. Simpson (1998)
Mechanisms of Cardiac Dysfunction Associated With Tyrosine Kinase Inhibitor Cancer Therapeutics
M. Chen (2008)
American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects.
J. Carver (2007)
Chemotherapy-induced lung disease.
A. Limper (2004)
Radiation induced heart disease
P. Heidenreich (2009)
Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma.
S. Schey (2004)
Effect of letrozole on the lipid profile in postmenopausal women with breast cancer.
M. Elisaf (2001)
Vascular toxicity associated with cisplatin.
M. King (2003)
The spectrum of 5-fluorouracil cardiotoxicity
J. Dalzell (2009)
Cardiac Toxicity of 5-Fluorouracil: A Study on 1083 Patients
R. Labianca (1982)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
R. Motzer (2007)
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme
M. Pfeffer (2003)
Review of tests for monitoring doxorubicin-induced cardiomyopathy.
W. Ganz (1996)
Late-onset pulmonary fibrosis and chest deformity in two children treated with cyclophosphamide.
C. Alvarado (1978)
Severe bleomycin lung toxicity: reversal with high dose corticosteroids.
J. Maher (1993)
Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer.
H. Gómez (2008)
Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy.
Matthew C. Hull (2003)
Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study
R. Alikhan (2003)
THE EFFECTS OF RADIATION THERAPY ON PULMONARY FUNCTION IN CARCINOMA OF THE LUNG.
L. Brady (1965)
Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients.
B. Barlogie (2001)
Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.
M. Cohen (2002)
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
P. Richardson (2006)
Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.
A. Chobanian (2003)
Prognostic Value of Troponin I in Cardiac Risk Stratification of Cancer Patients Undergoing High-Dose Chemotherapy
D. Cardinale (2004)
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
B. Pitt (1999)
Hypercholesterolemia after chemotherapy for testis cancer.
D. Raghavan (1992)
Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.
M. O'Brien (2004)
Pulmonary toxicity associated with erlotinib.
V. Liu (2007)
A Phase I-II Study to Determine the Maximum Tolerated Infusion Rate of Rituximab with Special Emphasis on Monitoring the Effect of Rituximab on Cardiac Function
M. Siano (2008)
Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.
H. Burstein (2003)
Pulmonary fibrosis following therapy with Melphalan for multiple myeloma
B. Codling (1972)
Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy.
M. Zangari (2002)
Phase II trial of gemcitabine plus trastuzumab in metastatic breast cancer patients previously treated with chemotherapy: preliminary results.
J. O'Shaughnessy (2002)
Cardiotoxicity of interferon. A review of 44 cases.
M. Sonnenblick (1991)
Cardiac toxicity: old and new issues in anti-cancer drugs
M. Sereno (2008)
Prevention of High-Dose Chemotherapy-Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition
D. Cardinale (2006)
Prophylactic and therapeutic anticoagulation for thrombosis—major issues in oncology
M. Carrier (2009)
Vindesine-associated angina and ECG changes.
R. J. Yancey (1982)
Heart failure associated with sunitinib malate
A. Khakoo (2008)
The cardiotoxic potential of the 5-HT(3) receptor antagonist antiemetics: is there cause for concern?
D. Keefe (2002)
Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis.
B. Hutten (2000)
Deep venous thrombosis and thalidomide therapy for multiple myeloma.
K. Osman (2001)
Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma.
M. Duvic (2001)
Cardiac Toxicity of High-Dose Cyclophosphamide in Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation
S. Zver (2007)
Capecitabine-associated coronary vasospasm: a case report
C. Papadopoulos (2008)
Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis.
X. Zhu (2007)
Anterior leaflet repair with patch augmentation for mitral regurgitation.
M. Romano (2005)
Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.
S. Swain (1997)
Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial.
E. Perez (2008)
Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840.
A. Seidman (2008)
Side Effects of Ifosfamide
J. Klastersky (2003)
Cardiac morbidity of adjuvant radiotherapy for breast cancer.
D. Patt (2005)
Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial.
T. Suter (2007)
Cardiotoxicity of Histone Deacetylase Inhibitor Depsipeptide in Patients with Metastatic Neuroendocrine Tumors
M. Shah (2006)
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
O. Abe (2005)
Results of a Phase II trial of oral bexarotene (Targretin) combined with interferon alfa‐2b (Intron‐A) for patients with cutaneous T‐cell lymphoma
D. Straus (2007)
Screening for coronary artery disease after mediastinal irradiation for Hodgkin's disease.
P. Heidenreich (2007)
Adverse effects of bevacizumab and their management in solid tumors.
Y. Arriaga (2006)
Sunitinib in patients with metastatic renal cell carcinoma.
R. Motzer (2006)
Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.
G. Batist (2001)
Safety of Non-Antiarrhythmic Drugs that Prolong the QT Interval or Induce Torsade de Pointes
F. Ponti (2002)
Coronary artery disease mortality in patients treated for hodgkin's disease
J. F. Boivin (1992)
Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial.
H. Mouridsen (2007)
Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis.
S. R. Nalluri (2008)
Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion.
S. Legha (1982)
Protective effects of carvedilol against anthracycline-induced cardiomyopathy.
N. Kalay (2006)
A case of cardiogenic shock caused by capecitabine treatment
A. C. To (2008)
Cardiac Studies in Patients Treated with Depsipeptide, FK228, in a Phase II Trial for T-Cell Lymphoma
R. Piekarz (2006)
Acute Pulmonary Embolism
S. Konstantinides (2000)
Cardiac surgery after mediastinal radiation: extent of exposure influences outcome.
A. S. Chang (2007)
Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: results of a phase I trial.
M. Untch (2004)
S. Sleijfer (2001)
Assessment of coronary heart disease morbidity and mortality after radiation therapy for early breast cancer.
K. Vallis (2002)
Radiation pneumonitis following combined modality therapy for lung cancer: analysis of prognostic factors.
M. Roach (1995)
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
A. Lee (2003)
Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience.
V. Guarneri (2006)
Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma.
B. Cheson (2008)
Mortality from myocardial infarction after adjuvant radiotherapy for breast cancer in the surveillance, epidemiology, and end-results cancer registries.
L. Paszat (1998)
Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS).
A. Kakkar (2004)
Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy.
J. Cuzick (1994)
Pulmonary toxicity from novel antineoplastic agents.
I. Dimopoulou (2006)
Cardiac toxicity following thoracic radiation.
R. Prosnitz (2005)
Discriminative ability of conventional echocardiography and tissue Doppler imaging techniques for the detection of subclinical cardiotoxic effects of treatment with anthracyclines.
L. Kapusta (2001)
Long-term cardiac and pulmonary complications of cancer therapy.
J. Yahalom (2008)
Does this patient have deep vein thrombosis?
P. Wells (2006)
Phase II evaluation of adriamycin in human neoplasia
R. O'bryan (1973)
This paper is referenced by
Compendium of Mechanistic Insights of Distinct Conventional Anticancer Therapies and Their Grievous Toxicities
S. A. Ganai (2020)
Histone Deacetylase Inhibitors in Combinatorial Anticancer Therapy
S. A. Ganai (2020)